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Abstract
Background: Green tea was suggested as a therapeutic agent for the treatment of diabetes more than 70 years
ago, but the mechanisms behind its antidiabetic effect remains elusive. In this work, we address this issue by
feeding a green tea extract (TEAVIGO™) with a high content of epigallocatechin gallate (EGCG) or the
thiazolidinedione PPAR-g agonist rosiglitazone, as positive control, to db/db mice, an animal model for diabetes.
Methods: Young (7 week-old) db/db mice were randomized and assigned to receive diets supplemented with or
without EGCG or rosiglitazone for 10 weeks. Fasting blood glucose, body weight and food intake was measured
along the treatment. Glucose and insulin levels were determined during an oral glucose tolerance test after 10
weeks of treatment. Pancreata were sampled at the end of the study for blinded histomorphometric analysis. Islets
were isolated and their mRNA expression analyzed by quantitative RT-PCR.
Results: The results show that, in db/db mice, EGCG improves glucose tolerance and increases glucose-stimulated
insulin secretion. EGCG supplementation reduces the number of pathologically changed islets of Langerhans,
increases the number and the size of islets, and heightens pancreatic endocrine area. These effects occurred in
parallel with a reduction in islet endoplasmic reticulum stress markers, possibly linked to the antioxidative capacity
of EGCG.
Conclusions: This study shows that the green tea extract EGCG markedly preserves islet structure and enhances
glucose tolerance in genetically diabetic mice. Dietary supplementation with EGCG could potentially contribute to
nutritional strategies for the prevention and treatment of type 2 diabetes.
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Introduction
The WHO and CDC (U.S. Center for Disease Control)
predict that by today some 26 million people in the U.S.
only are afflicted by diabetes (http://www.cdc.gov/dia-
betes/). Previously viewed as a disease of the elderly,
type 2 diabetes is now seen in ever-younger age groups.
In the U.S. about one third of all newly diagnosed dia-
betes in children and adolescents (age 10-19 years) now
is type 2, an alarming scenario considering the magni-
tude of premature cardiovascular and cerebrovascular
morbidity in these individuals. Recent estimates by the
CDC indicate that the life-time risk of getting diabetes
is not less than 40% for people born in 2000 in the U.S.,
with certain ethnic groups being significantly overrepre-
sented (http://www.cdc.gov/diabetes). In the U.S. alone,
the annual cost for diabetes care is $174 billion, of
which 97% is targeted to type 2 diabetes (http://www.
cdc.gov/diabetes).
Second only to water, tea is the most consumed bev-
erage in the world and its beneficial properties have
been widely explored. Green tea has for centuries been
used in folk remedy to treat a number of ailments such
as diabetes. However, the precise mechanisms by which
green tea exerts its salutary effects remain unknown.
The tea leaf is rich in tea polyphenols, accounting for
25-35% of the dry weight. The flavonoid EGCG
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important one and is considered the main active ingre-
dient of green tea [1]. Over the past few decades, there
has been growing interest in EGCG, because it has been
suggested to exert an array of beneficial cardiovascular
influences [2-6]. The exact mechanism of action of
EGCG with regard to these various effects is largely
unknown and in many cases is assumed to be due to its
antioxidant activity.
It was previously shown that EGCG ameliorates cyto-
kine-induced b cell damage in vitro [7] and prevents the
decrease of islet mass induced by treatment with multi-
ple low doses of streptozotocin (STZ) in vivo [8]. How-
ever, in the latter study STZ was co-injected with
EGCG, which possesses strong antioxidative activity [9].
It is unclear whether the protective effects observed in
this study were due to direct inactivation of the co-
injected STZ. In contrast to these studies indicating an
antioxidative capacity of EGCG, investigations in the
insulinoma cell line HIT-T15 showed that EGCG treat-
ment was associated with increased production of reac-
tive oxygen species and reduced cell viability [10].
Thus, the antidiabetic effects of EGCG are not entirely
clarified. The in vivo relevance of potentially antidiabetic
green tea catechins remains to be demonstrated, parti-
cularly with regard to b cell function. Therefore, we
conducted an in vivo study in the db/db mouse to
explore the antidiabetic effects of dietary supplementa-
tion with a pharmacological dose of the most abundant
green tea catechin, EGCG. In addition, we have also
performed ex vivo analysis of pancreatic islets and
MIN6 cells treated with palmitate in combination with
EGCG. The reported results show that, by adding
EGCG to diet, the progression to glucose intolerance in
db/db mice can be prevented.
Material and methods
Animal care
The present study was approved by the local Animal
Ethics Committee. The investigation conformed to the
National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals [DHHS Publication No.
(NIH) 85-23, Revised 1985, Office of Science and Health
Reports, Bethesda, MD 20892]. All animals were main-
tained on a 12 h light (300 Lux) and 12 h dark cycle at
a humidity of 55-60% and a temperature of 23 ± 1°C.
All db/db animals received modified AIN-93 diets (Pro-
vimi Kliba AG, Kaiseraugst, Switzerland) [11] and water
ad libitum.
Experimental design in vivo
The effect of dietary EGCG (TEAVIGO™,D S MN u t r i -
tional Products Ltd, Basel, Switzerland) supplementation
on type-2-like diabetes was investigated by utilizing the
db/db diabetic mouse model (BKS.Cg m
+/+ Lepr
db).
TEAVIGO™ is a highly purified extract from green tea
leaves (Camellia sinensis) containing > 94% EGCG, <
5% other catechins (< 3% epicatechin gallate). Male (7
weeks old) db/db mice (Jackson Laboratories, Bar Har-
bor, ME) were randomized to receive placebo diet, a
modified AIN-93 diet containing EGCG at a concentra-
tion of 10 g/kg of diet (EGCG 1% [w/w]) or a diet con-
taining the thiazolidinedione rosiglitazone (Avandia™,
GlaxoSmithKline, Brentford, UK) at a concentration of
21 mg/kg of diet (Rosi 0.0021% [w/w]) for 10 weeks.
Fasting (2 hour) blood glucose levels were measured at
0, 5 and 10 weeks, food intake and body weight were
monitored at 0, 3, 6 and 9 weeks. After 10 weeks of
dietary treatment, an oral glucose tolerance test (OGTT)
was performed. Before application of an oral glucose
load (1 g/kg, Sigma, St. Louis, MO), blood glucose levels
were determined in food-deprived animals (Glucotrend,
Roche Diagnostics, Basel, Switzerland). Plasma insulin
was determined by use of an ELISA kit (Mercodia AB,
Uppsala, Sweden). Insulin resistance was assessed by
either homeostasis model assessment-estimated insulin
resistance (HOMA-IR) = fasting glucose (mM) * fasting
insulin (μU/ml)/22.5, or by quantitative insulin sensitiv-
ity check (QUICKI) = 1/[log ((fasting glucose (mg/dl) +
(fasting insulin (μU/ml))]. After the OGTT, animals
were sacrificed and pancreas was taken for further
experiments.
Pancreas histology and insulin content
The pancreas of each animal was carefully dissected, a
small part of the splenic part of the gland was weighed
and placed in acid ethanol (0.18 M HCl in 95% ethanol)
to determine insulin content and the rest was immersed
in formalin solution and stored at 4°C until further pro-
cessing for histological examination. Preparations were
fixed in 4% buffered neutral formalin, embedded in par-
affin and cut at 4 μm. The pancreas was cut on three
different levels (each 100 μm apart) for both the splenic
and the duodenal part to get a representative overview.
So in total, there were 6 measurements that were aver-
aged. A part of the sections was stained with hematoxy-
lin and eosin (HE). The other sections were
immunolabeled with antiinsulin antibodies. For this pur-
pose, sections were deparaffinized and re-hydrated, and
then incubated for 25 minutes in 70% methanol and
hydrogen peroxide (H2O2). After washing with Tris-buf-
fer-saline (TBS, pH 7.3), the sections were incubated
overnight at 4°C with an antiinsulin antibody (Serotec,
Inotech AG, Dottikon, Switzerland) in TBS + 10%
bovine serum, dilution 1:1000 and then for 90 minutes
with an antiguinea pig antibody (Vectastain, Vector,
Reactolab SA, Servion, Switzerland) in TBS + 10%
bovine serum, dilution 1:200. After washing, sections
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tain, Vector, Reactolab SA, Servion, Switzerland) for 150
minutes and then washed again. The sections were
stained with 3,3 diaminobenzidin (DAB) for 5 minutes
and counter-stained with hemalum (Mayer) for 45
seconds.
On each section, the total number of islets and the
relative number of pathological islets (in %) were deter-
mined. Pathological islets were defined by islet atrophy
due to loss of islet cells. This is histologically recogniz-
able as an abnormally small size and shrinkage of the
islet, characterized by loss of definition of islet bound-
aries and displacement of exocrine tissue (single cells,
acini, ducts) into the islet tissue. Evaluation was per-
formed with a Nikon Eclipse E400 microscope (Nikon
AG, Egg, Switzerland).
The relative number of islets (per cm
2 of pancreas),
average islet size (in μm
2), relative endocrine area (in %
of the pancreatic surface), and relative b cell area (in %
of the whole endocrine surface) were determined with
software (program Stereo Investigator, Williston, VT).
The different areas were assessed with the Cavalieri
method. Briefly, this method allows estimation of a sur-
face area with the help of a grid placed over that sur-
face. The surface to be evaluated is divided in multiple
squares of equal size by this way. The surface area to be
estimated is then equal to the number of intersection
points of the lines of the grid which hit that surface,
multiplied by the area of one square. The smaller the
squares are chosen, and the higher the number of inter-
section points, the more accurate the estimation will be
and the closer to the real size of the surface. Histological
pictures were taken with a Nikon digital camera DXM
1200 (Nikon AG, Egg, Switzerland). All evaluations were
performed by an independent observer blinded to the
treatment of the animals.
Pancreas insulin content was measured after neutrali-
zation with an ELISA kit (Mercodia AB, Uppsala,
Sweden).
Culture of isolated islets and MIN6 cells
For ex vivo studies, 6 months old male C57Bl/6J mice
obtained from our local breed were used. Pancreatic
islets were isolated by collagenase digestion. Individual
islets were handpicked and placed in RPMI 1640 culture
medium (SVA, Uppsala, Sweden) containing 11 mM
glucose and supplemented with 10% FBS, 2 mM L-glu-
tamine and 60 μg/ml penicillin G and 50 μg/ml strepto-
mycin sulfate for an overnight recovery at 37°C and 5%
CO2. On the next day, islets were transferred to same
type of media but with 1% FBS and in the absence or
presence of 0.5 mM palmitate complexed with 0.5%
fatty acid free BSA (Boehringer Mannheim GmbH,
Mannheim, Germany) and with or without 5, 10 or 20
μM EGCG (prepared from 20 mM stock dissolved in
DMSO). Islets were exposed for 24 hours.
MIN6 cells (22), derived from mouse pancreatic b
cells, were maintained in Dulbecco’s Modified Eagle
Medium containing 25 mM glucose and sodium pyru-
vate supplemented with 15% FBS, 6 mg/ml penicillin G,
5 mg/ml streptomycin sulfate (Invitrogen Inc., Carlsbad,
CA), 2 mM L-glutamine (SVA, Uppsala, Sweden) and
50 μM b-mercaptoethanol at 37°C and 5% CO2. During
palmitate exposure, media was supplemented with 0.5
mM palmitate and 0.5% fatty acid-free BSA.
Islet and MIN6 mRNA analyses
Islets were isolated, by collagenase digestion of pan-
creata (see above), from db/db mice after 10 weeks of
dietary placebo, rosiglitazone or EGCG supplementation.
Islets from 9 mice in each group were pooled into 4
independent samples. After isolation, islets were washed
twice in PBS and then total mRNA was extracted using
Aurum™ Total RNA Mini kit (Bio-Rad, Hercueles, CA)
according to the manufacturer’s instructions and rever-
sely transcribed with iScript™ cDNA Synthesis kit (Bio-
Rad). Quantitative real-time PCR was performed in 20
μl volume containing ~25 ng cDNA, 0.5 μmol/l forward
and reverse primers and 10 μli Q ™ SYBR
® Green
Supermix (Bio-Rad). RNA isolation, cDNA synthesis and
qPCR of MIN6 exposed to palmitate in the absence or
presence of EGCG were performed as with islets. Pri-
mers used for the amplification are shown in Table 1.
PCR products were quantified fluorometrically using
SYBR Green and normalized to the housekeeping gene
b-actin and relative to the placebo group [12].
Assessment of cell viability and apoptosis
Cell viability was assayed with the Cytotoxicity Detec-
tion Kit (Plus Roche Diagnostics GmbH, Mannheim,
Germany). The assay measures the amount of lactate
dehydrogenase released from cells after lysis, which cor-
relates inversely to the amount of live cells after treat-
ment. Apoptosis was assayed with the cell death
detection kit ELISA
PLUS (Roche Diagnostics GmbH,
Mannheim, Germany). The ELISA measures cytoplasmic
oligonucleosomes that increase after apoptosis-asso-
ciated DNA degradation.
Western blot analysis
Samples of total protein extracted from untreated and
treated islets or MIN6 cells were subjected to SDS-
PAGE (15-20 μg protein per sample). After electrophor-
esis, proteins were transferred onto PVDF membranes.
Immunoblot analyses were performed with antibodies
against phosphorylated JNK 1/2, total JNK1/2 and the
cleaved form of caspase 3 (all obtained from Cell Signal-
ing Inc.). Immunoreactive bands were developed using
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Quantity One software (Bio-Rad). After imaging, to ver-
ify equal protein loading, the PVDF membranes were
stained with Coomassie.
Statistical analysis
All data are expressed as means ± SEM for animals in
each group. Statistical significance of the mean differ-
ences between groups was tested by one-way analysis of
variance (ANOVA). P values less than 0.05 were consid-
ered significant.
Results
Blood glucose, food intake and body weight during 10
weeks of treatment with EGCG or rosiglitazone
Data on fasting blood glucose, accumulated food intake
and body weight during the diet treatment of db/db
mice is given in Table 2. Fasting blood glucose levels in
7 weeks old db/db mice were approximately 5 mM
prior to treatment. During the 10 week treatment period
fasting blood glucose levels rose 3-fold in control mice
ending at 14.7 mM. Significantly lower fasting blood
glucose levels were seen in mice receiving either EGCG
or rosiglitazone after 10 weeks of treatment. In control
mice body weight increased from 21.9 to 46.0 gram dur-
ing the study period. Mice having a diet supplemented
with rosiglitazone gained more weight, ending at 60.4
gram. On the contrary, mice treated with EGCG had a
slightly lower body weight (42.2 gram) compared to
control mice. There was no difference in food intake
when comparing control mice and mice treated with
EGCG. Mice receiving rosiglitazone consumed more
food compared to control mice.
Glycemic control and plasma insulin levels after 10 weeks
of treatment with EGCG or rosiglitazone
Fasting glycemia, plasma insulin values and glucose and
insulin profiles during OGTT are shown in Figure 1 for
db/db mice treated with EGCG or rosiglitazone for 10
weeks. Animals receiving EGCG or rosiglitazone had
Table 1 Analysis of islet and MIN6 cell mRNA expression
db/db islets MIN6 cells
Gene name Control Rosi EGCG Control EGCG Palmitate EGCG
+Palmitate
Forward Reverse
Cpt-1 100 ±
21
36 ±
12*
25 ±
9*
100 ±
10
79 ± 3 1182 ±
90*
615 ± 46# 5’-
GATCTACAATTCCCCTCTGC-3’
5’-
CCTCTGTGGTACACGACAAT-
3’
Glut-2 100 ±
10
78 ± 19 70 ±
24
100 ± 2 102 ±
9
33 ± 1* 32 ± 3 5’-TGGCTTTCACTGTCTTCACT-
3’
5’-
GTGCCATTGACGTCATAGTT-
3’
Glucokinase 100 ± 9 123 ± 5 83 ±
10
100 ± 5 88 ±
13
89 ± 5 60 ± 8 5’-
GGCACGAAGACATAGACAAG-
3’
5’-
CACCACATCCATCTCAAAGT-
3’
Ddit3 100 ±
19
111 ±
16
61 ±
5*
100 ±
19
74 ±
14
646 ± 25* 485 ± 73# 5’-
TCTGTCTCTCCGGAAGTGTA-3’
5’-
CTGGTCTACCCTCAGTCCTC-3’
Ppp1r15a 100 ± 7 98 ± 4 71 ±
5*
100 ± 6 91 ± 7 1004 ±
57*
628 ± 50# 5’-TTCTATCTCCTGTCCCCACT-
3’
5’-
TACCAGAGACAGGGGTAGGT-
3’
Cdkn1a 100 ±
23
88 ± 19 43 ±
11*
100 ±
18
150 ±
43
439 ± 51* 579 ± 26 5’-
ATTGCTCAGACCTGTGAAGA-
3’
5’-
AGCAGCAGATCACCAGATTA-
3’
Pdx1 100 ±
16
90 ± 8 86 ±
10
-- - - 5 ’-
CCCTGAGCTTCTGAAAACTT-3’
5’-
AGCCCAGGTTGTCTAAATTG-
3’
Insulin 1 100 ±
15
126 ±
23
58 ±
10*
100 ± 3 103 ±
5
64 ± 4* 51 ± 2# 5’-
AGGTAGGCAACCGTGTAAAT-
3’
5’-
ACCTTCCTCTCAGGAGTCAG-
3’
Glucagon 100 ±
11
216 ±
30*
46 ±
7*
-- - - 5 ’-
GATTTTGTGCAGTGGTTGAT-3’
5’-
ACTTCTTCTGGGAAGTCTCG-
3’
Somatostatin 100 ±
13
116 ±
21
39 ±
4*
-- - - 5 ’-
TCTGGAAGACATTCACATCC-
3’
5’-
CAATTTCTAATGCAGGGTCA-
3’
Analysis of mRNA expression in islets of Langerhans isolated from control db/db mice and db/db mice receiving dietary supplementation with 1% (w/w) EGCG or
0.0021% (w/w) rosiglitazone (Rosi) for 10 weeks. The mRNA levels of the indicated genes were normalized to the levels of b-actin mRNA and expressed as mean
percent ± SEM of the control group, n = 4. * denotes P < 0.05 for a chance difference vs controls and # denotes P< 0.05 for a chance difference vs palmitate
using one-way ANOVA. MIN6 cells were exposed in vitro for 48 hrs to EGCG (20 μM), palmitate (0.5 mM) or a combination thereof
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similar fasting plasma insulin levels (Figure 1B) after 10
weeks of treatment with EGCG or rosiglitazone com-
pared with non-treated animals. Glycemic excursions
(Figure 1C and 1D) during the OGTT were significantly
smaller in animals receiving EGCG or rosiglitazone than
in control mice, and essentially normalized at the end of
the OGTT. Conversely, insulin responses (Figure 1E and
1F) to the OGTT were enhanced in EGCG- or rosiglita-
zone-treated animals. When insulin sensitivity was
Table 2 Fasting blood glucose, accumulated food intake and body weight during the diet treatment of db/db mice
Fasting blood glucose (mM) Body weight (gram) Food intake (gram/day and mouse)
Weeks on diet Weeks on diet Weeks on diet
0 5 1 0 0 36936 9
Control 5.1 ± 0.6 7.7 ± 0.9 14.7 ± 1.8 21.9 ± 1.4 30.6 ± 0.6 38.7 ± 0.6 46.0 ± 0.7 3.7 ± 0.1 3.5 ± 0.1 3.3 ± 0.1
Rosi 4.9 ± 0.5 4.0 ± 0.3* 6.1 ± 1.0* 24.5 ± 1.0 39.6 ± 0.9* 51.3 ± 0.7* 60.4 ± 0.7* 3.7 ± 0.1 4.2 ± 0.2* 4.0 ± 0.2*
EGCG 5.1 ± 0.4 6.2 ± 0.9 9.3 ± 1.1* 22.7 ± 0.5 30.9 ± 0.5 37.5 ± 0.5 42.2 ± 0.5* 3.6 ± 0.2 3.5 ± 0.1 3.2 ± 0.05
Analysis of fasting blood glucose, body weight and food intake in control db/db mice and db/db mice receiving dietary supplementation with 1% (w/w) EGCG or
0.0021% (w/w) rosiglitazone (Rosi) for up to 10 weeks. Data is expressed as mean ± SEM for 9 mice in each group. * denotes P < 0.05 for a chance difference vs
controls using one-way ANOVA in conjunction with Dunnett’s multiple comparison test
Figure 1 Improved glycemic control in db/db mice after 10 weeks of treatment with EGCG or rosiglitazone.M i c er e c e i v e dd i e t a r y
supplementation with 1% (w/w) EGCG or 0.0021% (w/w) rosiglitazone (Rosi) for 10 weeks. Shown are fasting blood glucose levels (A), fasting
plasma insulin levels (B), blood glucose concentrations (C, D) and plasma insulin concentrations (E, F) during an oral glucose tolerance test
(OGTT). Raw data from OGTT are presented in C and E while calculated area under the curve is presented in D and F for blood glucose and
plasma insulin respectively. Values represent mean ± SEM for 9 mice in each group. * denotes P < 0.05 for a chance difference vs controls using
one-way ANOVA in conjunction with Dunnett’s multiple comparison test.
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that rosiglitazone enhanced insulin sensitivity signifi-
cantly following 10 weeks of oral treatment. In contrast,
EGCG failed to significantly improve insulin sensitivity
after 10 weeks of treatment (Figure 2).
Islet histomorphometry
During progression to diabetes islet structure degenerate
[13]. To evaluate if EGCG and/or rosiglitazone were
able to prevent islet degeneration in the db/db mouse
model we used light microscopy to examine islet struc-
ture after insulin immunostaining. As shown in Figure
3, 10 weeks of EGCG treatment caused a significant
although not to same extent as rosiglitazone, decrease in
the number of islets showing pathological changes.
Treatment with EGCG for 10 weeks did not significantly
influence the size of the b cell area relative to the total
endocrine area in islets, whereas rosiglitazone modestly
increased b cell area. After 10 weeks of EGCG treatment
there was a significant increase in the number of islets
per area of pancreas, of comparable magnitude to that
evoked by rosiglitazone (Figure 4). Lastly, as shown in
Figure 5, 10 weeks of EGCG treatment caused a signifi-
cant increase in the size of the pancreatic islets, again of
comparable magnitude to that evoked by rosiglitazone.
Together with the hyperplastic effects of the substances
noted in Figure 4, this gave rise to > 2-fold increase in
pancreatic endocrine area. The presence of isolated,
invasive acinar cells among the endocrine cells in the
islets from untreated mice (Figure 5, left panel) suggests
that these are degenerated islets. Note the sparsely
granulated endocrine and heavily granulated acinar cells
located within the degenerate islets. In contrast, note
Figure 2 Changes in insulin resistance after 10 weeks of
treatment with EGCG or rosiglitazone. Peripheral insulin
sensitivity was assessed in control db/db mice and db/db mice
receiving a diet supplemented with 1% (w/w) EGCG or 0.0021% (w/
w) rosiglitazone (Rosi) for 10 weeks. Insulin resistance was evaluated
by two different means: Shown in A is homeostasis model
assessment-estimated insulin resistance (HOMA-IR) that was
calculated as fasting glucose (mM) * fasting insulin (μU/ml)/22.5.
Quantitative Insulin Sensitivity check (QUICKI) is shown in B and was
calculated as 1/[log ((fasting glucose (mg/dl) + (fasting insulin (μU/
ml))]. Bars represent mean ± SEM for 9 mice in each group. *
denotes P < 0.05 for a chance difference vs controls using one-way
ANOVA in conjunction with Dunnett’s multiple comparison test.
Figure 3 Effects of 10 weeks of treatment with EGCG or
rosiglitazone on pancreatic islet morphology and b cell area.
Light microscopic appearance and histomorphometric analysis of
pancreatic islet morphology and b-cell area in control db/db mice
and db/db mice receiving dietary supplementation with 1% (w/w)
EGCG or 0.0021% (w/w) rosiglitazone (Rosi) for 10 weeks. H&E
staining was used and original magnification was 200 x. Bars
represent mean ± SEM for 9 mice in each group. * denotes P <
0.001 (number of pathological islets) and P < 0.01 (b cell area) for
chance differences vs controls using one-way ANOVA in
conjunction with Dunnett’s multiple comparison test.
Figure 4 Increased number of pancreatic islets after 10 weeks
of treatment with EGCG or rosiglitazone. Light microscopic
appearance of pancreatic islets immunostained for insulin in control
db/db mice and db/db mice receiving dietary supplementation with
1% (w/w) EGCG or 0.0021% (w/w) rosiglitazone (Rosi) for 10 weeks.
Islets are immunostained for insulin (brown) and original
magnification was 100 x. Bars represent mean ± SEM for 9 mice in
each group. * denotes P < 0.05 for a chance difference vs controls
using one-way ANOVA in conjunction with Dunnett’s multiple
comparison test.
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apparently normal morphology of islets from mice trea-
ted with EGCG (middle) and rosiglitazone (right).
Pancreatic insulin content in control db/db mice was
0.9 ± 0.1 U insulin per gram pancreas wet weight. Diet
treatment with EGCG or rosiglitazone increased pan-
creatic insulin content to 1.6 ± 0.1 U/gram and 1.9 ±
0.1 U/gram, respectively. Although these increases were
not statistically significant (P =0 . 0 9 ,N=9 ) ,t h e s e
observations are nonetheless consistent with the histolo-
gical data.
Islet mRNA levels after 10 weeks of treatment with EGCG
or rosiglitazone
Quantitative real-time RT-PCR was used to analyze
mRNA expression of genes involved in glucose sensing,
endoplasmic reticulum stress, cell proliferation and
genes for pancreatic hormones in islets derived from
db/db mice fed a control diet or diets supplemented
with either EGCG or rosiglitazone (Table 1). Islet
mRNA expression of Glut-2 and glucokinase was not
affected by EGCG or rosiglitazone. On the other hand,
both supplements caused an approximately 65% reduc-
tion in islet L-CPT-1 mRNA levels. We also measured
mRNA levels of endoplasmic reticulum (ER) stress-asso-
ciated genes, whose levels are reported to be up-regu-
lated in the db/db mice [14,15]. Dietary
supplementation with EGCG, but not rosiglitazone,
reduced the expression of DNA-damage inducible tran-
script 3 (Ddit3), growth arrest and DNA-damage induci-
ble protein 34 (Ppp1r15a) and cyclin-dependent kinase
inhibitor 1a (Cdkn1a). We also monitored the levels of
Pdx1 mRNA, which, however, were not different
between the groups. Finally, we analyzed mRNA levels
of islet hormones insulin, glucagon and somatostatin.
Rosiglitazone up-regulated the levels of glucagon. All
hormone mRNA levels were lowered in islets derived
from db/db mice fed an EGCG-supplemented diet.
Western blot analysis of pancreatic islets exposed to
palmitate and EGCG ex vivo
The effects of EGCG alone and on palmitate-induced
cytotoxicity were investigated by measuring JNK phos-
phorylation and cleaved caspase 3 in isolated pancreatic
islets exposed to palmitate and EGCG ex vivo. After 24
hours, palmitate induced a 2 to 3-fold increase in JNK1
and JNK2 phosphorylation, which was accompanied
with a 3-fold induction of the cleaved form of caspase 3
(Figure 6) thus reflecting apoptosis. Neither 5 nor 10
μM of EGCG had any effect on palmitate-induced cyto-
toxicity, while 20 μM of EGCG caused a slight increase
in JNK phosphorylation and cleaved caspase 3, both in
the absence or presence of palmitate (Figure 6).
Effect of palmitate and EGCG in vitro in MIN6 cells
The effect of EGCG alone or in combination with pal-
mitate was also investigated in vitro in clonal pancreatic
MIN6 cells. Analysis of mRNA expression in MIN6 cells
after exposure to EGCG, in the absence or presence of
0.5 mM of palmitate, for 48 hours confirmed most of
the data seen in islets derived from db/db mice fed a
diet supplemented with EGCG (Table 1). While EGCG
per se was neutral, the compound reduced palmitate-
induced expression of ER stress-associated genes Ddit3
and Ppp1r15a, as well as palmitate-induced expression
of CPT-1. EGCG did not affect expression of Cdkn1a,
Glut-2 or glucokinase but exacerbated the reduction of
insulin-1 mRNA seen after palmitate treatment. EGCG
alone increased cell viability in MIN6 cells (data not
shown) and reduced palmitate-induced toxicity as evi-
denced by reduction in formation of cleaved caspase 3
and DNA fragmentation (Figure 7A and 7B), suggesting
EGCG protection against palmitate-induced apoptosis.
However, as with primary islets, EGCG was unable to
influence palmitate-induced activation of JNK signaling
(Figure 7C and 7D).
Discussion
In this study pre-diabetic db/db mice were given dietary
supplementation of EGCG or rosiglitazone. After 10
weeks of diet treatment mice treated with EGCG or
Figure 5 Increased size and endocrine area of pancreatic islets
after 10 weeks of treatment with EGCG or rosiglitazone. Light
microscopic appearance of pancreatic islets immunostained for
insulin in control db/db mice and db/db mice receiving dietary
supplementation with 1% (w/w) EGCG or 0.0021% (w/w)
rosiglitazone (Rosi) for 10 weeks. Islets are immunostained for insulin
(brown) and original magnification was 200 x. Bars represent mean
± SEM for 9 mice in each group. For islet size, * denotes P < 0.001,
and for endocrine area P < 0.01, for chance differences vs controls
using one-way ANOVA in conjunction with Dunnett’s multiple
comparison test.
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OGTT. Islet architecture was also preserved in mice
receiving any of the two compounds. Our findings sug-
gest that EGCG and rosiglitazone treatment may have
attenuated death of b cells in the db/db mouse. In this
strain of diabetic mice, EGCG and rosiglitazone treat-
ment was associated with increases in insulin content
and with preservation of islet and b cell architecture
and granulation. Similar results in morphology and
granulation have been observed in other animal models
of diabetes when treated with rosiglitazone [16]. The
results of our study are also in line with published data,
which suggest that EGCG preserves and protects the
islets [7,8]. However, our data also show that EGCG has
a limited effect ex vivo with regards to its ability to pro-
tect from palmitate-induced cytotoxicity. At a high con-
centration in vitro it can even display cytotoxic effects
to isolated islets of Langerhans, which are in concor-
dance with at least one previous study [10]. Therefore, it
is likely that dietary EGCG exerts its antidiabetic activity
both through a reduction of insulin resistance and an
increase in glucose-induced insulin secretion via protec-
tion of functional b cell mass. Euglycemic-hyperinsuline-
mic clamp studies for the determination of endogenous
glucose production, gluconeogenesis and glycogenolysis
will provide further understanding on the relative
importance of improved insulin sensitivity and b cell
function in the EGCG action.
We investigated mRNA levels in islet isolated from
control mice and mice treated with either EGCG or
rosiglitazone diet supplementation. Data shows that
EGCG, like rosiglitazone, lowers islet expression levels
of the mitochondrial fatty acid transporter L-Cpt-1. It is
possible that reduced L-Cpt-1 expression is a
Figure 7 EGCG in vitro partially protects MIN6 cells from
palmitate-induced apoptosis but does not influence palmitate-
induced phosphorylation of JNK. MIN6 cells were treated with 0.5
mM palmitate in the absence or presence of 20 μM EGCG for 48
hours. Western blot analysis of formation of the apoptosis marker
cleaved caspase 3 (A), phosphorylation of JNK1 (C) and JNK2 (D).
DNA fragmentation (B) was measured with an ELISA against
cytoplasmic oligonucleosomes. Bars represent mean ± SEM for 4
different cell preparations in each group. * denotes P < 0.05 for a
palmitate effect, and # denotes P < 0.05 for an EGCG effect using
one-way ANOVA in conjunction with Dunnett’s multiple comparison
test. Representative blots for phosphorylated JNK1 (p-JNK1),
phosphorylated JNK2 (p-JNK2) and cleaved caspase 3 (CC3) are
shown in E.
Figure 6 EGCG treatment of isolatedi s l e t so fL a n g e r h a n sex
vivo fails to prevent palmitate-induced phosphorylation of JNK
and formation of cleaved caspase 3. Pancreatic islets were
isolated from lean C57Bl/6J mice and exposed ex vivo for 24 hours
in the absence or presence of 0.5 mM palmitate with or without 5,
10 or 20 μM EGCG. Western blot analyses for phosphorylation of
JNK1 (A), JNK2 (B) and formation of the apoptosis marker cleaved
caspase 3 (C). Bars represent mean ± SEM for 5 different islet
preparations in each group. * denotes P < 0.05 for a palmitate
effect, and # denotes P < 0.05 for an EGCG effect using one-way
ANOVA in conjunction with Dunnett’s multiple comparison test.
Representative blots for phosphorylated JNK1 (p-JNK1),
phosphorylated JNK2 (p-JNK2) and cleaved caspase 3 (CC3) are
shown in D.
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as has been observed after EGCG and rosiglitazone feed-
ing of db/db mice [18]. Reduced L-Cpt-1 expression
would positively affect glucose-induced insulin secretion
[19]. Our data do not provide support for enhanced glu-
cose sensing after EGCG or rosiglitazone treatment,
since neither the expression of the glucose transporter
Glut-2, nor the glycolysis rate limiting enzyme glucoki-
nase, was affected. ER stress is associated with both
insulin resistance and pancreatic b cell dysfunction in
several obese animal models of type 2 diabetes
[14,15,20], of which the db/db mouse is one. Further-
more, increased expression of ER stress markers has
been reported from some [14], but not all [21], post
mortem examinations of human islets obtained from
type 2 diabetic patients. Among the various ER stress
markers, Ddit3 (also known as CHOP or GADD153)
links ER stress to cellular apoptosis and, conversely,
Ddit3 deletion reduces oxidative stress, improves b cell
function and ameliorates b cell apoptosis in db/db mice
[15]. Thus, our observation that dietary supplementation
with EGCG reduces islet Ddit3 expression and its down-
stream target Ppp1r15a, as well as Cdkn1a, provides a
plausible mechanistic explanation for the preserved islet
morphology seen in the EGCG group. These findings
were also true in MIN6 cells in vitro and can account
for the cytoprotective effect of EGCG against palmitate-
induced apoptosis seen in this cell line. From our data,
it is also evident that the antidiabetic effect of rosiglita-
zone could not be attributed to reduced expression of
Ddit3, Ppp1r15a or Cdkn1a. The mRNA levels of islet
hormones were unexpectedly lowered in the EGCG
group compared to the control group. Given the clear
antidiabetic phenotype incurred by EGCG treatment,
these results are surprising and we have not performed
experiments to address the reason behind.
Antidiabetic properties of green tea have been known
for some time. In the 1980s, it was reported that the
green tea constituent EGCG protects pancreatic islets
from alloxan by inducing restoration of blood glucose
concentrations and by promoting b cell regeneration in
the islets of alloxan-treated rats [22-24]. Furthermore,
EGCG was reported to stimulate insulin secretion and
to have insulin-like activity [25-27]. In previous work
evaluating the effect of EGCG against diabetes induced
in rats by the b cell toxin STZ, EGCG restored the dia-
betic state to normal as in other reports [23,24,28].
More recently, green tea and green tea extracts were
demonstrated to beneficially modify glucose metabolism
in experimental models of type 2 diabetes [29,30]. Two
previous in vivo studies have suggested a glucose-lower-
ing effect of EGCG [18,31]. In one of these [31], EGCG
was injected into lean and obese Zucker rats ensuring
supra pharmacologic plasma concentrations of EGCG
and resulted in markedly decreased blood glucose and
insulin levels. However, it is unclear whether these
observations were due to a direct glucose lowering effect
of EGCG or an anorectic effect caused by elevated
plasma concentrations of EGCG. Our study extends
these findings to also demonstrate a protection and pre-
servation of pancreatic b cell function and islet mor-
phology. Similar to previous findings in diet-induced
obesity models [32], EGCG supplementation in db/db
mice did not influence food intake. Thus, we can
exclude that EGCG enhanced glucose tolerance simply
by reducing food intake.
Conclusions
In conclusion, this study demonstrates that a pharmaco-
logical dose of the green tea catechin, EGCG, possesses
pronounced antidiabetic efficacy in vivo - comparable to
the effect seen with rosiglitazone-in a mouse model of
type 2 diabetes. The effects of EGCG are at least par-
tially mediated via reduced insulin resistance and
enhanced pancreatic islet function, the latter involving
reduction in ER stress markers. The results also indicate
that total plasma EGCG levels shown to be efficacious
in mice and rats can be reached by dietary supplementa-
tion of EGCG. Therefore, our results imply that treat-
ment of humans with type 2 diabetes with purified
EGCG could be a way to confer b cell protection. This
hypothesis should be investigated in randomized pla-
cebo-controlled trials.
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